Posts Tagged ‘bivalirudin’


August 18th, 2014

Selections from Richard Lehman’s Literature Review: August 18th

This week’s topics include the three sodium studies from NEJM, the CLARIFY study, and more.

July 14th, 2014

Can Bivalirudin Stand the HEAT?

Harlan Krumholz interviews Peter Berger, an editorialist for the HEAT-PPCI study, about the paper’s findings.

July 7th, 2014

HEAT-PPCI: Heparin Beats Bivalirudin in Primary PCI

Although there is broad consensus in the medical community that primary PCI is the best treatment for MI patients when it can be delivered promptly, there is no agreement about the best accompanying drug regimen, which usually entails a combination of antiplatelet and antithrombotic drugs. The role of one antithrombotic, bivalirudin (Angiomax, The Medicines Company) has […]

October 31st, 2013

EUROMAX Meets Primary Endpoint But Editorialist Raises Questions

When started during transport to the hospital during a heart attack, bivalirudin (Angiox, Medicines Company) improves clinical outcomes and reduces major bleeding, though at the cost of a small but significant risk in stent thrombosis. The results of the European Ambulance Acute Coronary Syndrome (ACS) Angiography) Trial (EUROMAX) were presented on Wednesday by Phillippe Gabriel […]

April 11th, 2013

Bleeding Avoidance Strategies for PCI in Women vs. Men


John Ryan interviews Stacie Daugherty, lead author of a study recently published online by JACC on differences in rates of bleeding and bleeding avoidance strategies (BAS) between women and men undergoing PCI. THE STUDY Investigators used data from the CathPCI registry to analyze the use of BAS (radial access, bivalirudin, vascular closure devices, or any combination) and […]

November 13th, 2011

ISAR-REACT 4: Bivalirudin Works Great, Less Bleeding

In the previously published REPLACE-2 and ACUITY trials, a trend was noted towards an increased incidence of ischemic complications with bivalirudin compared with glycoprotein IIb/IIIa treatment in high-risk patients undergoing PCI. The Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 4 (ISAR-REACT 4) trial was designed to show whether abciximab plus unfractionated […]